Results 41 to 50 of about 412,177 (358)

Allergic bronchopulmonary aspergillosis: diagnostic and treatment challenges [PDF]

, 2016
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder, occurring mostly in asthmatic and cystic fibrosis patients, caused by an abnormal T-helper 2 lymphocyte response of the host to Aspergillus fumigatus antigens.
CINICOLA, BIANCA LAURA, DUSE, MARZIA, Laitano, Rossella, LEONARDI, LUCIA   +3 more
core   +1 more source

Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial [PDF]

, 2020
Compelling data have linked disease progression in patients with idiopathic pulmonary fibrosis (IPF) with lung dysbiosis and the resulting dysregulated local and systemic immune response.
A Mishra, AW Brown, B Ley, BA Karimi-Shah, BT Baxter, CJ Ryerson, DG Pankratz, DJ Lederer, G Raghu, G Raghu, H Scheper, HR Collard, J Andrade, J Coast, J Coast, K Loudon, K Loudon, KA Getz, KD Brandt, KE Thorpe, KF Schulz, L Richeldi, L Shulgina, LB Krupp, M Fralick, M Hammond, MA Fischl, MA Perazella, MO Paterniti, MT Durheim, P Bhattacharyya, PL Molyneaux, PL Molyneaux, PL Molyneaux, R Dal-Ré, RM Califf, RM du Bois, SD Nathan, SS Birring, T Katsuyama, TE King Jr, VA Varney, WS Jones, Y Huang   +43 more
core   +1 more source

Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study

Medicines, 2021
Current FDA-approved antifibrotic treatments for Idiopathic Pulmonary Fibrosis slow down disease progression but have little impact on symptoms or quality of life in patients.
Neha Shah
doaj   +1 more source

How personality influences health outcomes and quality of life in adult patients with cystic fibrosis

BMC Pulmonary Medicine, 2023
Background The present study evaluates personality traits in adult patients with cystic fibrosis (CF) and correlates these results with health-related quality of life (HRQoL) and other clinical parameters indicative of disease severity.
Ute Niehammer, Svenja Straßburg, Sivagurunathan Sutharsan, Christian Taube, Matthias Welsner, Florian Stehling, Raphael Hirtz   +6 more
doaj   +1 more source

Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. [PDF]

, 2011
OBJECTIVE: The origin of the mesenchymal cells responsible for the intimal fibrosis in systemic sclerosis (SSc) has not been fully identified. The present study was undertaken to investigate whether subendothelial mesenchymal cells may emerge through ...
Jimenez, Sergio A., Li, zhaodong
core   +2 more sources

Polydatin ameliorates ovalbumin‐induced asthma in a rat model through NCOA4‐mediated ferroautophagy and ferroptosis pathway

FEBS Open Bio, EarlyView.
In this research, a rat model of asthma was created using OVA, and polydatin served as an intervention. By inhibiting ferroautophagy mediated by NCOA4 and averting ferroptosis, polydatin has been demonstrated to reduce asthma. This work presents new ideas for investigating the mechanism of polydatin's ability to alleviate asthma, in addition to ...
Wei Li, Yuwei Tang, Wenkang Liu, Fang Fang, Jiepeng Wang, Chaoyi Fang   +5 more
wiley   +1 more source

Oxidative stress in the pathogenesis of systemic scleroderma: An overview [PDF]

, 2018
Systemic sclerosis (SSc) is a rare disorder of the connective tissue characterized by fibrosis of the skin, skeletal muscles and visceral organs. Additional manifestations include activation of the immune system and vascular injury. SSc causes disability
Gambardella, Lucrezia, Giovannetti, Antonello, Malorni, Walter, Pietraforte, Donatella, Straface, Elisabetta, Vona, Rosa   +5 more
core   +1 more source

Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024

FEBS Open Bio, EarlyView.
The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior, Michaela Kocholata, Marilena E. Lekka, Olga Janouskova, Moran Yadid, Maja Kosanovic   +5 more
wiley   +1 more source

Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD). Methods The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS ...
Craig M. McDonald, Michela Guglieri, Dragana Vučinić, Gyula Acsadi, John F. Brandsema, Claudio Bruno, Erika L. Finanger, Amy Harper, Mercedes Lopez Lobato, Riccardo Masson, Nuria Muelas, Francina Munell, Yoram Nevo, Yann Péréon, Han Phan, Valeria A. Sansone, Mariacristina Scoto, Tracey Willis, Richard S. Finkel, Krista Vandenborne, Sara Cazzaniga, Silvia Montrasio, Federica Alessi, Paolo Bettica, Eugenio Mercuri, for the Givinostat Study 51 Investigators, the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS) Investigators, the ImagingDMD Investigators, Enrico Bertini, Giacomo Pietro Comi, Eugenio Maria Mercuri, Giuseppe Vita, Sonia Messina, Claudio Bruno, Riccardo Masson, Valeria Sansone, Nathalie Goemans, Liesbeth De Waele, Laurent Servais, Teresa Gidaro, Odile Boespflug‐Tanguy, Yann Péréon, Jessika Johannsen, Astrid Blaschek, Ulrike Schara‐Schmidt, Erik Niks, Imelda de Groot, Saskia Houwen‐van Opstal, Andres Nascimento, Juan Jesus Vilchez, Nuria Muelas, Francina Munell, Marcos Madruga Garrido, Mercedes Lopez Lobato, Michaela Guglieri, Tracey Willis, Stefan Spinty, Daniel Hawcutt, Mariacristina Scoto, Jean K. Mah, Laura McAdam, Kathryn Selby, Katherine Mathews, Craig McDonald, Craig Zaidman, Barry Byrne, John Brandsema, Gyula Acsadi, Chamindra Laverty, Amy Harper, Erika Finanger, Han Phan, Yoram Nevo, Vedrana Milic Rasic, Dragana Vucinic   +74 more
wiley   +1 more source

Nintedanib for systemic sclerosis–associated interstitial lung disease [PDF]

, 2019
BackgroundInterstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects ...
Alves, Margarida, Azuma, Arata, Clerisme-Beaty, Emmanuelle, Distler, Oliver, Fischer, Aryeh, Gahlemann, Martina, Girard, Mannaig, Highland, Kristin B., Kuwana, Masataka, Maher, Toby M., Mayes, Maureen D., Raghu, Ganesh, Sauter, Wiebke, SENSCIS Trial Investigator, for the, Smith, Vanessa, Stowasser, Susanne, Tetzlaff, Kay   +16 more
core   +3 more sources